Agent exhibits ‘significant evidence of efficacy’ for infants with severe hemophilia A

ByAshley Killen

Fact checked byMindy Valcarcel, MS

NEW ORLEANS — Emicizumab-kxwh prophylaxis appeared effective and safe for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

Analyses showed “significant evidence of efficacy” with emicizumab-kxwh (Hemlibra, Genentech) for this patient population, researcher Steven W. Pipe, MD, professor of pediatrics and pathology at University of Michigan, told Healio.

In this video, Pipe summarizes the study findings and their potential implications.

Published by:

Sources/Disclosures

Collapse

Source:

Pipe SW, et al. Abstract 187. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Disclosures: Pipe reports research funding from Siemens and YewSavin. He also reports consulting roles with Bayer, CSL Behring, Genentech/Roche, Novo Nordisk, Pfizer, Sanofi, Takeda and several other companies.

ASH Annual Meeting and Exposition

Read more

Agent exhibits ‘significant evidence of efficacy’ for infants with severe hemophilia A

Related Content